Stevanato Group S.p.A. (NYSE:STVN – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company.
Several equities research analysts recently weighed in on STVN shares. William Blair restated an “outperform” rating on shares of Stevanato Group in a research report on Friday, March 7th. UBS Group lowered their target price on shares of Stevanato Group from $24.00 to $23.50 and set a “neutral” rating for the company in a research note on Friday, March 7th. Finally, Stephens raised shares of Stevanato Group to a “strong-buy” rating in a research report on Monday, April 21st.
Read Our Latest Report on Stevanato Group
Institutional Trading of Stevanato Group
Stevanato Group Price Performance
Shares of NYSE:STVN opened at €24.58 ($28.25) on Friday. The company has a market capitalization of $7.44 billion, a P/E ratio of 52.30, a P/E/G ratio of 7.18 and a beta of 0.53. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21. Stevanato Group has a 1-year low of €16.56 ($19.03) and a 1-year high of €25.75 ($29.60). The firm’s 50 day simple moving average is €22.13 and its two-hundred day simple moving average is €21.54.
Stevanato Group Increases Dividend
The company also recently disclosed an annual dividend, which will be paid on Thursday, July 17th. Shareholders of record on Thursday, June 5th will be paid a $0.0613 dividend. This is a boost from Stevanato Group’s previous annual dividend of $0.05. This represents a yield of 0.3%. The ex-dividend date is Thursday, June 5th. Stevanato Group’s payout ratio is currently 11.76%.
Stevanato Group Company Profile
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
Featured Stories
- Five stocks we like better than Stevanato Group
- High Dividend REITs: Are They an Ideal Way to Diversify?
- AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Casey’s Surges on Strong Q4, More Gains Likely Ahead
- Buy P&G Now, Before It Sets A New All-Time High
- Government Mandate Sends eVTOL Stocks Flying
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.